Biotech Most Volatile: Aastrom Biosciences (NASDAQ:ASTM), CytRx Corporation (NASDAQ:CYTR), Imprimis Pharmaceuticals (NASDAQ:IMMY), Idenix Pharmaceuticals (NASDAQ:IDIX)



Aastrom Biosciences Inc (NASDAQ:ASTM)’s shares declined 19.11% to $5.25. The company announced that Nick Colangelo, President and CEO of Aastrom, will present at the 2014 Regen Med Investor Day on March 26 at 3:15 p.m. EDT at the Metropolitan Club in New York City. Aastrom Biosciences Inc (NASDAQ:ASTM) stock performance was -2.95% in last session and finished the day at $4.93. Traded volume was 975,204 million shares in the last session and the average volume of the stock remained 318.89 million shares. The beta of the stock remained 0.75. Aastrom Biosciences Inc (NASDAQ:ASTM) insider ownership is 3.27%.

CytRx Corporation (NASDAQ:CYTR) has  announced it has initiated a pivotal global Phase 3 clinical trial to evaluate the efficacy and safety of aldoxorubicin as a second-line treatment for patients with soft tissue sarcoma (STS) under a Special Protocol Assessment with the FDA. Aldoxorubicin combines the chemotherapeutic agent doxorubicin with a novel linker-molecule that binds specifically to albumin in the blood to allow for delivery of higher amounts of doxorubicin (3.5 to 4 times) without several of the major treatment-limiting toxicities seen with administration of doxorubicin alone. CytRx Corporation (NASDAQ:CYTR) dropped -7.52 percent to $3.69 yesterday on volume of 2.91 million shares. The intra-day range of the stock was $3.66 to $4.17. CytRx Corporation (NASDAQ:CYTR) has a market capitalization of $205.03 million.

Imprimis Pharmaceuticals, Inc (NASDAQ:IMMY) a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to participate at two growth investor conferences during the month of March. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)’s stock on Mar 25, 2014 reported a increase of 7.26% to the closing price of $7.53. Its fifty two weeks range is $3.01 -$10.00. The total market capitalization recorded $67.55 million. The overall volume in the last trading session was 46,196 million shares. In its share capital, Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) has 8.96 million outstanding shares.

Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) announced that it intends to file an appeal to challenge the Oslo, Norway District Court’s (the “Court”) decision in a patent invalidity case concerning Idenix’s co-owned Norwegian patent NO 330 755 that covers certain 2′-methyl-2′-fluoro nucleoside compounds useful in the treatment of the hepatitis C virus (HCV) and other flaviviridae infections. On Tuesday, shares of Idenix Pharmaceuticals Inc (NASDAQ:IDIX) dropped -5.97% to close the day at $6.30. Company return on investment (ROI) is -116.60% and its monthly performance is recorded as -11.52%. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) quarterly revenue growth is 16.88%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone